MailMyPrescriptions is a licensed and accredited US Pharmacy with the following Certifications:
Powered by GeniusRx
How does an FSA work?
Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Methscopolamine bromide is used as an adjunct in the treatment of peptic ulcer disease. As with other antimuscarinics, there are no conclusive data from well-controlled studies that indicate that, in the usually recommended dosage, methscopolamine aids in the healing, decreases the rate of recurrence, or prevents complications of peptic ulcers. In addition, in patients with gastric ulcer, antimuscarinics may delay gastric emptying and result in antral stasis. With the advent of more effective therapies for the treatment of peptic ulcer disease, antimuscarinics have only limited usefulness in this condition. Current epidemiologic and clinical evidence supports a strong association between gastric infection with Helicobacter pylori and the pathogenesis of duodenal and gastric ulcers, and the American College of Gastroenterology (ACG), the National Institutes of Health (NIH), and most clinicians currently recommend that all patients with initial or recurrent duodenal or gastric ulcer and documented H. pylori infection receive anti-infective therapy for treatment of the infection. For a more complete discussion of H. pylori infection, including details about the efficacy of various regimens and rationale for drug selection,
Dosage and Administration
Methscopolamine bromide is administered orally. The drug is preferably given 30 minutes before meals and at bedtime.
The usual initial adult dosage of methscopolamine bromide is 2.5 mg 3 times daily before meals and 2.5 or 5 mg at bedtime. The manufacturer states that in patients with a history of increased susceptibility to the adverse effects of antimuscarinics, therapy should be initiated at a low dosage. The manufacturer states that an initial total daily dose of 12.5 mg is effective in most patients. Patients with severe symptoms may be given an initial dosage of 20 mg daily, administered in divided 5-mg doses 3 times daily before meals and once at bedtime; the manufacturer states that some patients may tolerate 30 mg daily.
As with other antimuscarinics, higher than recommended dosage of methscopolamine bromide may be required for therapeutic effect. The drug should be carefully titrated until therapeutic effect is achieved or adverse effects become intolerable, using the lowest possible effective dosage.
If methscopolamine bromide is used in pediatric patients, a dosage of 0.2 mg/kg or 6 mg/m daily, given in 4 equally divided doses, has been recommended by some clinicians. However, the manufacturer states that safety and efficacy of the drug have not been established in pediatric patients.
Methscopolamine bromide, like other quaternary ammonium drugs, is incompletely absorbed from the GI tract since it is completely ionized.
Little information is available on the distribution or metabolic fate of methscopolamine bromide in the body. Quaternary ammonium antimuscarinics are completely ionized and possess poor lipid solubility. Accordingly, they do not readily penetrate the CNS or the eye. Methscopolamine bromide, like other quaternary ammonium compounds, is believed to be excreted principally in urine as unchanged drug and metabolites and in the feces as unabsorbed drug. Substantial amounts of orally administered drug are probably eliminated in feces as unabsorbed drug.